Speech-Language Pathologists in Greenwich, CT Accepting Medicare

24 Speech-Language Pathologists found. Showing 21 - 24

Ms. Alexandra Rose Matthews, M.A., CCC-SLP, TSSLD Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 100 Melrose Ave, Greenwich, CT 06830 Phone: 203-869-8272

Rebecca C Gutman Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 100 Melrose Ave Ste 100, Greenwich, CT 06830 Phone: 773-203-8965

Caitlin Eileen Wells, M.S. CCC-SLP, TSSLD Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 187 Weaver St, Greenwich, CT 06831 Phone: 201-787-6682

Miss Jessica Leigh Griffin, M.S. Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 100 Melrose Ave, Suite 201, Greenwich, CT 06830 Phone: 203-869-8272

News Archive

BIIR researchers report results of comparative study of molecular immune responses to influenza and pneumococcal vaccines

In a manuscript published today in Immunity, scientists at the Baylor Institute for Immunology Research (BIIR) and the Benaroya Research Institute at Virginia Mason report the results of a comparative study of the molecular immune responses to influenza and pneumococcal vaccines.

Telerent in top 100 US private independent equipment leasing and finance companies

Telerent Leasing Company, a North Carolina-based, independent leasing company specializing in hospitality and healthcare FF&E leases, has been recognized by Monitor Magazine, the leading publication in the equipment and finance industry, as one of the top 100 private independent equipment leasing and finance companies in the U.S. for the second consecutive year. Telerent placed 97th on the list, an increase of three positions from the 2008 rankings.

Accuracy of CT colonography is excellent in comparison with conventional colonoscopy for colorectal cancer screening

The diagnostic accuracy of CT colonography is excellent in comparison with conventional colonoscopy for colorectal cancer screening, an analysis of previous studies shows.

Pfizer extends JAK3 research collaboration with Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated announced today that its research collaboration with Pfizer for JAK3 has been extended by one year. The Research and License Agreement entered into in December 2006 with Wyeth provided for an initial three year research term. Under this extension, Ligand will receive $3.1 million in research payments to continue conducting drug discovery and lead candidate optimization.

Read more Medical News

› Verified 5 days ago

• 1
• 2(current)